海格投资 HTGC 深 沪
等待开盘 08-18 09:30:00 美东时间
19.06
-0.290
-1.50%
华盛通- 最 高19.33
- 今 开19.32
- 成交量 100.74万股
- 最 低 19.04
- 昨 收 19.35
- 总市值 33.35亿
- 52周最高 20.63
- 市盈率 静 11.84
- 换手率 0.58%
- 52周最低 14.71
- 委 比 88.24%
- 总股本 1.75亿
- 历史最高 20.63
- 量 比 0.76
- 振 幅 1.50%
- 历史最低 -4.31
- 每 手 1
- 风险率 2.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Heron Therapeutics announces capital restructuring to support growth
Heron Therapeutics (NASDAQ:HRTX) Friday reported the completion of a comprehensive capital restructuring designed to enhance the company's financial flexibility, reduce total debt, and support long-te...
08-08 20:41
JMP Securities Maintains Market Outperform on Hercules Capital, Raises Price Target to $24
JMP Securities analyst Devin Ryan maintains Hercules Capital (NYSE:HTGC) with a Market Outperform and raises the price target from $22 to $24.
08-04 19:58
Hercules Capital Announces Q2 2025 Cash Distribution
Hercules Capital ( ($HTGC) ) has provided an announcement. On July 29, 2025, He...
08-01 05:18
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Ares Capital declares $0.48 dividend
Ares Capital (NASDAQ:ARCC) declares $0.48/share quarterly dividend, in line with previous. Forward yield 8.46% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 15. See ARCC Dividend...
07-29 18:26
Adaptimmune Limited, A Subsidiary Of Adaptimmune Therapeutics Plc Announces It Entered Into An Asset Purchase Agreement With USWM CT, A Subsidiary Of US WorldMeds Partners, Llc, To Sell Assets And Rights Related To Its Cell Therapy Products Offer Employment To Approximately Half Of Adaptimmune's Workforce. In Exchange, UU WorldMeds Will Pay $55M In Cash
On July 27, 2025, Adaptimmune Limited ("Seller"), a wholly-owned subsidiary of Adaptimmune Therapeutics plc (together with Seller, "Adaptimmune" or the "Company"), entered into an Asset Purchase Agreement (the
07-28 19:49
UBS Maintains Neutral on Hercules Capital, Raises Price Target to $19
UBS analyst Vilas Abraham maintains Hercules Capital (NYSE:HTGC) with a Neutral and raises the price target from $18.5 to $19.
07-16 23:26
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
<p>Dyne Therapeutics secures a $275 million senior secured term loan facility with Hercules Capital to advance its DM1 and DMD programs, with $100 million upfront and additional funding tied to milestones. The financing supports clinical and regulatory progress, including potential U.S. Accelerated Approval submissions in 2026 and a first launch in DMD in 2027. Hercules Capital highlights its confidence in Dyne’s leadership and pipeline to addres...
06-30 20:01
NextTrip files to sell 2.37M shares of common stock by selling shareholders
NextTrip (NTRP) filed a prospectus to resale 2.37 million shares of common stock. The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. This prospectus...
06-21 05:15
Hercules Capital Completes $350M Public Offering
Hercules Capital ( ($HTGC) ) has issued an announcement. On June 16, 2025, Herc...
06-17 05:48
